Publication date: Jul 08, 2019
Antisense oligonucleotides represent a novel therapeutic platform for the discovery of medicines that have the potential to treat most neurodegenerative diseases. Antisense drugs are currently in development for the treatment of amyotrophic lateral sclerosis, Huntington’s disease, and Alzheimer’s disease, and multiple research programs are underway for additional neurodegenerative diseases. One antisense drug, nusinersen, has been approved for the treatment of spinal muscular atrophy. Importantly, nusinersen improves disease symptoms when administered to symptomatic patients rather than just slowing the progression of the disease. In addition to the benefit to spinal muscular atrophy patients, there are discoveries from nusinersen that can be applied to other neurological diseases, including method of delivery, doses, tolerability of intrathecally delivered antisense drugs, and the biodistribution of intrathecal dosed antisense drugs. Based in part on the early success of nusinersen, antisense drugs hold great promise as a therapeutic platform for the treatment of neurological diseases.
Bennett, C.F., Krainer, A.R., and Cleveland, D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. 18544. 2019 Annu Rev Neurosci (42):
|disease||DOID||spinal muscular atrophy|
|disease||MESH||spinal muscular atrophy|
|disease||DOID||amyotrophic lateral sclerosis|
|disease||MESH||amyotrophic lateral sclerosis|
- Immunoreactivity of myelin-associated oligodendrocytic basic protein in Lewy bodies.
- Exploring the frequency and clinical background of the “zebra sign” in amyotrophic lateral sclerosis and multiple system atrophy.